Cited by 251Reproductive tract infections researchHIV/AIDS Research and InterventionsCervical Cancer and HPV Research

Patient-Delivered Partner Treatment With Azithromycin to Prevent Repeated Chlamydia trachomatis Infection Among Women: A Randomized, Controlled Trial

SCHILLINGER, JULIA A., KISSINGER, PATRICIA, CALVET, HELENE, WHITTINGTON, WILLIAM L. H., RANSOM, RAY L., STERNBERG, MAYA R., BERMAN, STUART M., KENT, CHARLOTTE K. +6 more·2003·Sexually Transmitted Diseases

Abstract

BACKGROUND: Repeated infection with C trachomatis increases the risk for serious sequelae: pelvic inflammatory disease, ectopic pregnancy, infertility, and chronic pelvic pain. A substantial proportion of women treated for C trachomatis infection are reinfected by an untreated male sex partner in the first several months after treatment. Effective strategies to ensure partner treatment are needed. GOAL: The goal of the study was to determine whether repeated infections with C trachomatis can be reduced by giving women doses of azithromycin to deliver to male sex partners. STUDY DESIGN: A multicenter randomized controlled trial was conducted among 1,787 women aged 14 to 34 years with uncomplicated C trachomatis genital infection diagnosed at family planning, adolescent, sexually transmitted disease, and primary care clinics or emergency or other hospital departments in five US cities. Women treated for infection were randomized to one of two groups: patient-delivered partner treatment (in which they were given a dose of azithromycin to deliver to each sex partner) or self-referral (in which they were asked to refer their sex partners for treatment). The main outcome measure was C trachomatis DNA detected by urine ligase chain reaction (LCR) or polymerase chain reaction (PCR) by 4 months after treatment. RESULTS: The characteristics of study participants enrolled in each arm were similar except for a small difference in the age distribution. Risk of reinfection was 20% lower among women in the patient-delivered partner treatment arm (87/728; 12%) than among those in the self-referral arm (106/726; 15%); however, this difference was not statistically significant (odds ratio, 0.80; 95% confidence interval, 0.62-1.05; = 0.102). Women in the patient-delivered partner treatment arm reported high compliance with the intervention (82%). CONCLUSION: Patient-delivered partner treatment for prevention of repeated infection among women is comparable to self-referral and may be an appropriate option for some patients.

Integrity signals

Registry

Crossref · 10.1097/00007435-200301000-00011

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Across EPT trials, reductions in chlamydia prevalence at follow-up were approximately 20%, and reductions in gonorrhea were approximately 50% at follow-up.

    “However, across trials, reductions in chlamydia prevalence at follow-up were approximately 20%, and reductions in gonorrhea were approximately 50% at follow-up.”

    From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [126]

  • All three U.S. trials reported that more partners were treated when patients were offered EPT.

    “All three trials reported that more partners were treated when patients were offered EPT.”

    From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [126]

  • Two U.S. trials reported statistically significant decreases in the rate of reinfection, and one observed a lower risk for persistent or recurrent infection that was statistically nonsignificant.

    “Two reported statistically significant decreases in the rate of reinfection, and one observed a lower risk for persistent or recurrent infection that was statistically nonsignificant.”

    From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [126]

  • Evidence supporting EPT is based on three U.S. clinical trials involving heterosexual men and women with chlamydia or gonorrhea.

    “Evidence supporting EPT is based on three U.S. clinical trials involving heterosexual men and women with chlamydia or gonorrhea (125–127).”

    From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [126]

  • U.S. trials and a meta-analysis of EPT revealed that the magnitude of reduction in reinfection of index patients, compared with patient referral, differed according to the STI and the sex of the index patient.

    “U.S. trials and a meta-analysis of EPT revealed that the magnitude of reduction in reinfection of index patients, compared with patient referral, differed according to the STI and the sex of the index patient (110,125–127).”

    From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [126]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
SCHILLINGER, J. A., KISSINGER, P., CALVET, H., WHITTINGTON, W. L. H., RANSOM, R. L., STERNBERG, M. R., BERMAN, S. M., KENT, C. K., MARTIN, D. H., OH, M. K., HANDSFIELD, H. H., BOLAN, G., MARKOWITZ, L. E., & FORTENBERRY, J. D.
Affiliations
  • Centers for Disease Control and Prevention (US)
  • Tulane University (US)
  • Department of Health and Human Services (US)
  • University of Washington (US)
  • San Francisco Department of Public Health (US)
  • Louisiana State University Health Sciences Center New Orleans (US)
  • Public Health – Seattle & King County (US)
Corresponding author
  • SCHILLINGER, JULIA A.
  • RANSOM, RAY L.
  • STERNBERG, MAYA R.
  • BERMAN, STUART M.
  • HANDSFIELD, H. HUNTER
  • MARKOWITZ, LAURI E.
Venue
Sexually Transmitted Diseases
Published
2003-01
Volume
30
Issue
1
Pages
49-56
ISSN
0148-5717 (ISSN-L)
OpenAlex
W2072744471
Cited by
251
References
24
Citations by year
2026: 3 · 2025: 1 · 2024: 3 · 2023: 10 · 2022: 5 · 2021: 10 · 2020: 8 · 2019: 11 · 2018: 6 · 2017: 13 · 2016: 8 · 2015: 13 · 2014: 7 · 2013: 11 · 2012: 16
FWCI
12.32
Type
journal article
Language
en
Open access
closed
Locations
  • Sexually Transmitted Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Keywords
Chlamydia trachomatis, reinfection, azithromycin, partner notification, self-referral, women, sexually transmitted infections, chlamydia screening, intervention adherence
MeSH terms
Adolescent, Adult, Anti-Bacterial Agents, Chlamydia Infections, Chlamydia trachomatis, DNA, Bacterial, Drug Administration Schedule, Female, Humans, Male, Preventive Health Services, Recurrence, Sexual Partners, United States, Polymerase Chain Reaction, Azithromycin, Ligase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review